When people think about philanthropy, they often think about the moment a grant is awarded. The announcement is made. The funding is secured. Photos are taken. Everyone celebrates. Then what? That question doesn't get nearly enough attention. In biomedical research, a grant is rarely the finish line. More often, it's the starting point. Discoveries don't happen on a predictable schedule, and meaningful scientific progress almost never fits neatly into a two- or three-ye

When people think about medical breakthroughs, they often think about the discovery itself. A new therapy. A promising clinical trial. A scientific advancement that changes the way we understand disease. What often gets overlooked is where those breakthroughs begin. They usually start with people. Specifically, researchers willing to spend years asking difficult questions, testing ideas, and pursuing answers that may not come easily.

Most people think progress in cancer research happens in big moments. A breakthrough. A headline. A new treatment. What they don’t see is everything that happens before that. The years of work. The failed experiments. The collaboration across institutions. The early ideas that don’t yet have enough data to qualify for traditional funding. That’s where a lot of the real progress starts. And it’s where cancer research philanthropy can make a meaningful difference.

When people hear about a cancer research breakthrough, the story often sounds simple. A discovery is announced. A new therapy shows promise. A headline declares progress. But what most people don’t see behind cancer research breakthroughs is the long, demanding path that leads to that moment. Scientific progress rarely arrives in a single dramatic leap. It comes through years of incremental work, careful experimentation, and persistence from researchers who are trying to a

But what they don’t see is the grind behind the scenes. The years of effort, the research that doesn’t get funded, and the scientists struggling to keep momentum without institutional support.

Most people think of philanthropy as charity. I think of it as an investment, with an expected return measured in discoveries, not dollars. At the JKTG Foundation, we don’t fund cancer research the traditional way. We don’t issue massive RFPs or wait for consensus to form. We move quickly, prioritize bold thinkers, and stay close to the science. Why? Because the diseases we’re up against, like breast cancer, won’t wait.

You get results: faster, sharper, and more aligned with what patients truly need. That was the driving force behind the 9th annual JKTG Symposium, held October 15, 2025 in Washington D.C. This year’s theme, "Improving Breast Cancer Outcomes: Revealing and Targeting Tumor–Immune Interactions," was more than a title. It was a call to action.

If you want to slow progress down, wrap it in red tape. That’s the reality for far too much medical research in this country. Scientists with bold ideas spend more time formatting grant proposals than actually running experiments. And when the funding does come through, it’s often a year too late, tied up in approval cycles, institutional requirements, and layers of administrative overhead. The worst part? Some of the most promising ideas never even get submitted. They’re too

Every field has its trends, and science is no exception. One year, it’s immunotherapy. Next, it’s AI in diagnostics. Big breakthroughs and high-impact journals are great. But when funding begins to chase popularity instead of substance, something gets lost. The cost of chasing what’s popular in science is high. It’s paid by researchers working on foundational problems who can’t get funded. It’s paid by patients waiting for treatments that don’t check the right boxes. And it’s

There’s a habit in healthcare policy circles to treat hospitals as if they’re just another line item in the system. A vendor. A cost center. Something to cut, cap, or streamline. But hospitals are a lot more than that. They’re not just healthcare providers. They’re employers. Infrastructure anchors. Economic drivers. And in many communities, they’re the largest single source of jobs, stability, and social services. That’s not an argument for protecting the status quo. It’s a

If a project is safe, it will get funded. If it’s bold, uncertain, or disruptive, it probably won’t. That’s the problem. High-risk cancer research is exactly where the biggest breakthroughs often happen. But in most traditional funding models, the riskiest projects get pushed aside, not because they’re wrong, but because they don’t fit the system. This is where philanthropy comes in. And this is why the JKTG Foundation exists...

We throw the word legacy around a lot. People use it to mean all kinds of things: a name on a building, a career full of accolades, a foundation that writes checks in your honor. But in my experience, real legacy isn’t about how things look. It’s about whether what you built keeps working when you’re no longer in the picture. In cancer research, that’s especially important. If your funding, your connections, or your ideas are holding everything together, then you’re not build

For years, I’ve funded cancer research behind the scenes. Now, we’re taking the conversation public, with the launch of Driving Research, the JKTG Foundation’s first-ever cancer research podcast. And we’re starting with a conversation that matters...